Skip to main content

Table 4 Adjusteda odds ratio (OR) and 95% confidence interval (CI) for joint effect of BMI at age 18 years and recent BMI in relation to risk of breast cancer overall and luminal-like subtype in premenopausal women

From: Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis

BMI at age 18 years, kg/m2

Recent BMI, kg/m2

Controls

All cases

luminal-like (ER+ and/or PR+)

Number

Number

OR (95% CI)

Number

OR (95% CI)

Overall

    

 < 20.0

< 25.0

472

952

Referent

540

Referent

 < 20.0

25.0–29.9

96

184

0.93 (0.70–1.24)

92

0.79 (0.56–1.13)

 < 20.0

≥ 30.0

20

51

1.21 (0.69–2.13)

24

0.99 (0.50–1.96)

 20.0–24.9

< 25.0

265

555

1.03 (0.85–1.25)

311

1.00 (0.79–1.26)

 20.0–24.9

25.0–29.9

171

302

0.87 (0.69–1.10)

151

0.77 (0.58–1.02)

 20.0–24.9

≥ 30.0

107

210

0.86 (0.65–1.13)

115

0.84 (0.60–1.17)

 ≥  25.0

< 25.0

21

38

0.89 (0.50–1.58)

17

0.65 (0.32–1.35)

 ≥  25.0

25.0–29.9

32

47

0.75 (0.46–1.22)

26

0.79 (0.43–1.44)

 ≥  25.0

≥ 30.0

73

88

0.54 (0.38–0.78)

40

0.46 (0.29–0.73)

Restricted to studies in which cases’ ER/PR/HER2 status determined in a central laboratory

    

 < 20.0

< 25.0

342

448

Referent

183

Referent

 < 20.0

25.0–29.9

70

86

0.94 (0.66–1.35)

31

0.79 (0.49–1.29)

 <20.0

≥ 30.0

16

21

1.03 (0.52–2.05)

6

0.67 (0.25–1.83)

 20.0–24.9

< 25.0

186

253

1.05 (0.83–1.34)

103

1.03 (0.75–1.42)

 20.0–24.9

25.0–29.9

132

148

0.86 (0.65–1.15)

55

0.75 (0.51–1.11)

 20.0–24.9

≥ 30.0

81

89

0.78 (0.55–1.11)

37

0.79 (0.50–1.25)

 ≥ 25.0

< 25.0

15

23

1.09 (0.55–2.16)

8

0.83 (0.33–2.08)

 ≥ 25.0

25.0–29.9

27

23

0.68 (0.38–1.22)

11

0.76 (0.36–1.62)

 ≥ 25.0

≥ 30.0

58

41

0.52 (0.33–0.81)

15

0.46 (0.25–0.86)

Restricted to invasive cases

    

 < 20.0

< 25.0

472

849

Referent

485

Referent

 < 20.0

25.0–29.9

96

169

0.94 (0.70–1.26)

86

0.83 (0.58–1.20)

 < 20.0

≥ 30.0

20

51

1.35 (0.77–2.38)

24

1.13 (0.56–2.28)

 20.0–24.9

< 25.0

265

506

1.04 (0.85–1.27)

287

1.03 (0.81–1.32)

 20.0–24.9

25.0–29.9

171

286

0.92 (0.72–1.17)

143

0.84 (0.62–1.13)

 20.0–24.9

≥ 30.0

107

201

0.89 (0.67–1.18)

114

0.94 (0.67–1.34)

 ≥ 25.0

< 25.0

21

33

0.87 (0.48–1.59)

14

0.58 (0.27–1.26)

 ≥ 25.0

25.0–29.9

32

44

0.80 (0.48–1.32)

25

0.89 (0.48–1.66)

 ≥ 25.0

≥ 30.0

73

85

0.58 (0.40–0.84)

40

0.53 (0.33–0.85)

  1. Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor-2, BMI body mass index
  2. aORs obtained from multivariable polychotomous unconditional logistic regression models with adjustment for source study, study site, race, education, reference age, first-degree breast cancer family history, age at menarche, number of completed pregnancies, lifetime recreational physical activity, alcohol intake, cigarette smoking status, and oral contraceptive use